U.S. Psychedelic Drugs Market expected to reach USD 6,859.95 million by 2027 from USD 2,077.90 million in 2019 | DBMR
According to Data Bridge Market Research Jazz Pharmaceuticals, Inc. is the leader for U.S. psychedelic drugs market and this company holds estimated market share of approximately 70% to 80% of the market. The market leader Jazz Pharmaceuticals, Inc. accounts an estimated market share of approximately 75.00% in the U.S. Jazz Pharmaceuticals, Inc. is a leader in psychedelic drugs in the U.S. and additionally, the company is continuously involved in the development of new products to increase its portfolio of psychedelic drugs. The psychedelic drugs sales revenue of Jazz Pharmaceuticals, Inc. has increased drastically by 16% to generate sales revenue of USD 1,525.18 million 2019 as compared to 2018.
- In October 2018, Jazz Pharmaceuticals plc has received FDA Authorization for Xyrem (sodium oxybate) for the excessive daytime sleepiness or cataplexy treatment in pediatric narcolepsy patients. The authorization will help company to dominate the market as Xyrem is one and only FDA approved treatment available for cataplexy and excessive daytime sleepiness in narcolepsy for adult patients.
Trends impacting the market
The U.S. psychedelic drugs market is becoming more competitive every year with companies such as Johnson & Johnson Services, Inc. and Jazz Pharmaceuticals, Inc., the market leaders for U.S. psychedelic drugs Market. The data bridge market research new reports highlight the major growth factors and opportunities in the U.S. psychedelic drugs market.
Key Market Competitors Covered in the report
- Johnson & Johnson Services, Inc.
- Jazz Pharmaceuticals, Inc.
- Celon Pharma SA
- Develco pharma schweiz ag
- Doughlas pharmaceuticals limited
- NeuroRX, Inc.
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals, LLC.
- AVADEL PHARMACEUTICALS, PLC
Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=us-psychedelic-drugs-market
List of Table:
TABLE 1 MENTAL ILLNESS IN U.S. ADULTS IN 2018
TABLE 2 MENTAL DISORDERS IN THE U.S. ADULTS IN 2018
TABLE 3 MENTAL DISORDERS CAUSED BY USAGE OF SUBSTANCE DISORDERS IN WORLD IN 2017
TABLE 4 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS
TABLE 5 COST OF PSYCHEDELIC DRUGS
TABLE 6 PSYCHEDELIC DRUGS R&D ACTIVITIES
TABLE 7 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)
TABLE 8 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 9 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 10 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 11 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)
TABLE 12 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 13 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (VOLUME IN 100ML)
For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=us-psychedelic-drugs-market
List Of Figure:
FIGURE 1 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 2 U.S. PSYCHEDELIC DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 U.S. PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS
FIGURE 4 U.S. PSYCHEDELIC DRUGS MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. PSYCHEDELIC DRUGS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 8 U.S. PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 9 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION AND INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS ARE DRIVING THE U.S. PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 10 SYNTHETIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. PSYCHEDELIC DRUGS MARKET IN 2020 & 2027
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF U.S. PSYCHEDELIC DRUGS MARKET
FIGURE 12 MENTAL ILLNESS AMONG THE U.S. ADULTS IN 2018, BY DEMOGRAPHIC GROUP
Research Methodology: U.S. Psychedelic Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
- Demand Side: Dermatologists, Psychiatrists, Researchers, Practitioners, and activists, Academician, Distributors, Hospitals, Nurses, and Industrial Professionals.
- Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
About Data Bridge Market Research:
Data Bridge Market Research set forward itself as an offbeat and neoteric Market examination and advising firm with unrivaled level of solidarity and facilitated approaches. We have made plans to reveal the best market openings and empower powerful information for your business to thrive by keeping watch. Data Bridge attempts to offer reasonable responses for the confounding business troubles and starts a simple unique communication. Data associate is a consequence of sheer understanding and experience which was nitty gritty and illustrated in the year 2015 in Pune.
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
- CDN Newswire